Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline

Executive Summary

German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.

Advertisement

Related Content

4Q Pharma Results Preview, Part 3: Gilead, GSK, Sanofi, Allergan, Shire, Bayer, Valeant
Bayer Consumer Health Journey Still Short Of Destination
Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Is Bayer Making A Mistake With Monsanto When Pharma Is Its Leading Business?
Changes Brewing At Bayer, But Pharma Strategy Remains On Point
Dekkers: New Bayer Is Stable And Fit To Innovate for All Species

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097329

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel